Key facts
- Harness Therapeutics’s last known valuation is $31.5M (Jan 2022).
- It has raised $23.0M; the latest was Early Stage VC in Jan 2025.
- Notable investors include SV Health Investors, Takeda Ventures, BioIndustry Association, Epidarex Capital, Ono Venture Investment — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Harness Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Harness Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Harness Therapeutics
Developer of a biotechnology platform designed to help the physiological upregulation of important neurodegenerative targets. The company utilizes mRNA-targeted oligonucleotides to modulate post-transcriptional protein synthesis and deliver disease-modifying therapeutics for neurodegenerative diseases, enabling patients to achieve precise protein regulation and address conditions such as Huntington's disease and ALS/AD.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2020
- Employees
- 22
- Website
- harnesstx.com/
- Ownership
- Privately Held (backing)
Harness Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Harness Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Harness Therapeutics in its N-PORT filings yet. We sweep new filings monthly.